Caladrius Biosciences
NASDAQ: LSTABasking Ridge, US · Founded 2006 · Delaware corporation · 35 employees on LinkedIn
Find your way into Caladrius Biosciences
98 people in our graph share verified history with the Caladrius Biosciences team — schools, employers, funds. One of them is your warm intro.
Desmond Padhiunlockedknows David J. Mazzo · together at Schering-Plough Research Institute (overlapped)
knows the team · via University of Massachusetts Amherst
×2knows the team · via Lisata Therapeutics, Inc.
knows the team · via Celularity
×2knows the team · via Schering-Plough Research Institute
×4knows the team · via Seton Hall University
Lisata Therapeutics is a clinical-stage biopharmaceutical company developing certepetide, an investigational peptide designed to enhance the delivery and efficacy of anti-cancer drugs to solid tumors by activating a tumor-specific transport mechanism, while also modifying the tumor microenvironment to improve response to immunotherapy. The company is pursuing clinical development of certepetide in combination with chemotherapy and immunotherapy across multiple solid tumor types including pancreatic cancer, cholangiocarcinoma, and glioblastoma.
Founders & leadership
DJ
David J. MazzoinExecutiveDavid Mazzo holds a Ph.D. in analytical chemistry from the University of Massachusetts, Amherst, and has served as CEO of multiple biopharmaceutical companies including Regado Biosciences, Æterna Zentaris, and Chugai Pharma USA, as well as senior roles at Schering-Plough Research Institute, Hoechst Marion Roussel, and Rhone-Poulenc Rorer; he is currently President and CEO of Lisata Therapeutics.
JT
Joseph TalamoExecutive
RA
Robert A. PretiinExecutive
AL
Andrew L. PecorainExecutive
SW
Stephen W. PotterinExecutive
RD
Robert Dickey IVExecutive
CV
Catherine VaczyinExecutive
DL
KK
Kristen K. BuckinExecutive Vice President of Research & Development and Chief Medical Officer
JN
James NiscoinSenior Vice President Finance and Treasury and Chief Accounting Officer
Board
EW
Eric WeiBoard director
SS
Steven S. MyersBoard director
Reported raises · per SEC filings
Form D private placements$83.2M disclosed across 7 rounds · 2014–2021
▶$25MraisedFeb 2021 · 23 investors · BiotechnologyRule 506(b)
▶$25MraisedFeb 2021 · 23 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Steven M. KloskDirector
- Gregory B. BrownDirector
- Steven S. MyersDirector
- Cynthia SchwalmDirector
- Peter G. TraberDirector
- Anne WhitakerDirector
- David J. MazzoExecutive Officer, Director
- Michael DavidsonDirector
- Offering amount
- $25M
- Amount sold
- $25M
- Sales commissions
- $1.8M
- Placement agents
- H.C. Wainwright & Co., LLC3
- First sale
- Jan 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2MraisedJul 2020 · 3 investors · BiotechnologyRule 506(b)
▶$2MraisedJul 2020 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Joseph TalamoExecutive Officer
- Cynthia SchwalmDirector
- Peter G. TraberDirector
- Steven S. MyersDirector
- Steven M. KloskDirector
- David J. MazzoExecutive Officer, Director
- Douglas LosordoExecutive Officer
- Gregory B. BrownDirector
- Offering amount
- $2M
- Amount sold
- $2M
- First sale
- Jul 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.2MraisedJun 2020 · 6 investors · BiotechnologyRule 506(b)
▶$2.2MraisedJun 2020 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Douglas LosordoExecutive Officer
- Peter G. TraberDirector
- Gregory B. BrownDirector
- Joseph TalamoExecutive Officer
- David J. MazzoExecutive Officer
- Steven S. MyersDirector
- Cynthia SchwalmDirector
- Steven M. KloskDirector
- Offering amount
- $2.2M
- Amount sold
- $2.2M
- Sales commissions
- $301K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- May 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.4MraisedMay 2020 · 5 investors · BiotechnologyRule 506(b)
▶$2.4MraisedMay 2020 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Peter G. TraberDirector
- Steven M. KloskDirector
- Gregory B. BrownDirector
- Douglas LosordoExecutive Officer
- Cynthia SchwalmDirector
- David J. MazzoExecutive Officer
- Joseph TalamoExecutive Officer
- Steven S. MyersDirector
- Offering amount
- $2.4M
- Amount sold
- $2.4M
- Sales commissions
- $350K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Apr 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$12.6MraisedSep 2016 · 5 investors · BiotechnologyRule 506(b)
▶$12.6MraisedSep 2016 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David MazzoExecutive Officer, Director
- Peter TraberDirector
- Douglas LosordoExecutive Officer
- Joseph TalamoExecutive Officer
- Andrew L. PecoraDirector
- Steven M. KloskDirector
- Richard BermanDirector
- Steven S. MyersDirector
- Eric WeiDirector
- Robert A. PretiExecutive Officer, Director
- Offering amount
- $21M
- Amount sold
- $12.6M
- First sale
- Sep 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1MraisedMar 2016 · 3 investors · BiotechnologyRule 506(b)
▶$1MraisedMar 2016 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David J. MazzoExecutive Officer, Director
- Steven S. MyersDirector
- Joseph TalamoExecutive Officer
- Peter TraberDirector
- Robert A. PretiExecutive Officer, Director
- Steven M. KloskDirector
- Richard BermanDirector
- Eric WeiDirector
- Andrew L. PecoraDirector
- Offering amount
- $1M
- Amount sold
- $1M
- First sale
- Mar 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$38MraisedMay 2014 · 142 investors · BiotechnologyRule 506(b)
▶$38MraisedMay 2014 · 142 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert PretiExecutive Officer
- Stephen W. PotterExecutive Officer
- Martyn D. GreenacreDirector
- Robert Dickey IVExecutive Officer
- Richard BermanDirector
- Andrew L. PecoraExecutive Officer, Director
- Catherine VaczyExecutive Officer
- Joseph TalamoExecutive Officer
- Douglas LosordoExecutive Officer
- Drew BernsteinDirector
- Steven S. MyersDirector
- Eric H.C. WeiDirector
- Robin L. SmithExecutive Officer, Director
- Offering amount
- $38M
- Amount sold
- $38M
- Finders' fees
- $1.5M
- Placement agents
- Piper Jaffray & Co.
- First sale
- May 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Caladrius Biosciences do?
- Lisata Therapeutics is a clinical-stage biopharmaceutical company developing certepetide, an investigational peptide designed to enhance the delivery and efficacy of anti-cancer drugs to solid tumors by activating a tumor-specific transport mechanism, while also modifying the tumor microenvironment to improve response to immunotherapy. The company is pursuing clinical development of certepetide in combination with chemotherapy and immunotherapy across multiple solid tumor types including pancreatic cancer, cholangiocarcinoma, and glioblastoma.
- How much funding has Caladrius Biosciences raised?
- Caladrius Biosciences has disclosed $83.2M raised across 7 rounds.
- Where is Caladrius Biosciences headquartered?
- Caladrius Biosciences is headquartered in Basking Ridge, US.